Congress must roll back a key anti-innovation Biden-Harris policy
Though the U.S. continues to lead the world as a life science capital, outspending every country on earth in research and development, the Biden-Harris administration is running a relentless campaign against American innovation.
This includes its threats to exercise march-in rights to the Inflation Reduction Act price controls. As if this were not enough, the administration has pushed many promising cures into the so-called "valley of death," using unnecessary bureaucracy that devalues the importance of improving a patient’s overall quality of life.
Life science innovation is one of the most challenging and costly endeavors in the U.S. economy. For example, with an overall success rate of 16 percent and an average of $1 billion in research and development costs, it takes nearly a decade for a drug to achieve FDA approval. The aptly named "valley of death" is the gaping canyon between U.S. Food and Drug Administration approval and coverage of innovative therapies by the Centers for Medicare and Medicaid Services (CMS).
A two-pronged approach is needed to eliminate barriers to getting life-saving treatments to patients more quickly.
First, doubling down on FDA reform is essential. The key center reviewing drugs has 5,910 employees, only a fraction of which are directly involved in drug review. By trimming bureaucracy and collapsing middle management, FDA staff can return to its core role of reviewing new innovations to assess for safety and efficacy.
A more efficient FDA can provide customized guidance to innovators and entrepreneurs, helping to move clinical trials into the community setting, promote the use of real-world evidence with outcomes meaningful to patients, and reduce the burdens of data collection. The application of artificial intelligence to the first stage of drug review could massively reduce review time while preserving safety, ensuring that physicians at FDA are not fiddling with statistical software trying to program basic analyses.
FDA efficiency is only half the battle, since innovators must still confront an uncooperative CMS, which keeps finding excuses to deny coverage at every turn.
One strategy used by the agency is "Coverage with Evidence Development," which requires additional clinical trials on top of those conducted for the FDA. These requirements can span decades. Of the 27 devices or procedures subjected to this procedure since 2005, only four were not still undergoing it as of April 2022. The evidence development system has been corrupted. Originally designed to accelerate innovation, it now poses a huge obstacle. A moratorium on new Coverage with Evidence Development programs is needed until it can be fixed or scrapped. At the very least, these programs must have clearly marked completion criteria and fixed time limits.
CMS also demonstrates hostility toward drugs receiving FDA accelerated approval, which are placed on an expedited review pathway due to their potential to help vulnerable patients. Drugs like Leqembi were placed under Coverage with Evidence Development despite their likelihood to slow progression of early-stage Alzheimer’s. Under the Biden-Harris administration, CMS is building a platform to consistently second-guess FDA, floating a model to cut reimbursement for accelerated approval drugs.
Others go even further. The state of Oregon, for instance, applied for a Medicaid waiver to deny coverage for accelerated approval drugs while a congressional Medicaid advisory committee suggested requiring higher Medicaid rebates for these drugs. Use of the accelerated approval pathway must be encouraged if we want to change the lives of patients, and CMS should stop second-guessing FDA’s licensure decisions.
Sometimes CMS simply drags its feet. It took more than three years for the Independence iBOT Mobility System — a powered wheelchair that lets users navigate stairs and live a more normal life — to gain CMS coverage after FDA approval. Such unacceptably long waits motivated the Trump administration to grant temporary automatic coverage for up to four years for breakthrough medical devices.
Unfortunately, after entering office, the Biden-Harris administration almost immediately repealed this rule, and two years later issued its own narrower pathway, mirroring the poorly executed Coverage with Evidence Development program. Unlike the Trump administration’s policy, the Biden-Harris pathway accepts only five devices annually. Despite issuing the proposal over a year ago, the administration only finalized it this month, demonstrating the low priority it places on innovation. y
CMS got it right on the first try. Now Congress must pass legislation reinstating the Trump rule, so that patients can access novel medical technology.
At a time when cancer deaths in adults cost more than $94 billion in lost earnings, and the direct cost of diabetes care exceeds $306 billion, promoting life sciences innovation is an economic imperative. Innovation is also a moral imperative. The human cost is real, as every patient is someone’s spouse, child or friend.
Joe Grogan is a nonresident senior scholar at the USC Schaeffer Center and served as director of the Domestic Policy for former President Trump. He consults for pharmaceutical companies.
Dr. Brian J. Miller is a nonresident fellow at the American Enterprise Institute and an assistant professor of medicine at the Johns Hopkins University School of Medicine.
Date: | |
Tag: | Joe Biden |
Topics
-
The Guardian - World
Zelenskyy has a gamechanging plan to win peace. For it to work, Biden must back it – fast | Timothy Garton Ash
In besieged Kharkiv, I saw how Ukraine is approaching a perilous moment. To turn the tide, it first needs to decisively knock back Russia. Earlier this week, I started a 3,000km, two-day journey ...8 hours ago - Joe Biden -
The Hill - Politics
It’s almost too late to protect our elections from AI — Congress must act now
As AI becomes more widespread, the potential for electoral mischief will only grow.23 hours ago -
The Hill - Politics
White House rolls out ‘The Record’ to highlight Biden agenda online
The White House on Friday unveiled “The Record,” a new part of its website to highlight President Biden’s agenda during his four years in office. In an announcement sent exclusively to The Hill, ...Yesterday - Joe Biden -
CNBC - Business
Bank of Japan keeps key interest rate steady as it treads cautiously on normalizing policy
The decision came as the central bank seeks to wean its economy off the long-held ultra-easy monetary policy and curb the yen's slide against the U.S. dollar.Yesterday -
Inc. - Business
Civil Rights Groups Push Back on Anti-DEI Efforts
A collective of 19 organizations reminded top U.S. companies to maintain DEI programs is not only ethically right, but also beneficial to their businesses.Yesterday -
The New York Times - Top stories
Rallying in Two Key States, Harris Presses Her Case on Abortion Rights
Visiting Wisconsin after giving a speech in Georgia, the vice president signaled she would focus on the life-or-death risks of abortion bans in the final weeks of the race.14 hours ago - Abortion -
NBC News - Politics
Harris and Trump hit key swing states as early voting begins
Vice President Kamala Harris was in Georgia and Wisconsin on Friday with events centered on reproductive rights. While former President Donald Trump heads to the swing state of North Carolina on ...1 hour ago - Donald Trump -
The Guardian - World
Strikes inside Russia with US missiles key to Ukraine’s plan to end war, says Zelenskyy
Zelenskyy will present ‘victory plan’ to US president during trip to Washington next week, when he is also likely to hold talks with Trump. Volodymyr Zelenskyy has urged Joe Biden to allow Ukraine ...5 hours ago - Ukraine -
NBC News - Politics
Undecided voters, set in their views of Trump, now weigh backing Harris
Kenneth Hauck wasn’t sure how he would vote when the race between former President Donald Trump and Vice President Kamala Harris was just a hypothetical scenario.Yesterday
More from The Hill
-
The Hill - Politics
Trump goes off on Maher for 'sloppy and tired' attacks
Former President Trump slammed comedian Bill Maher, writing that the TV personality has become “sloppy and tired” and that his HBO show's topics tend to always include the GOP nominee. “The ...26 minutes ago - Donald Trump -
The Hill - Politics
The deadly consequences of Donald Trump’s anti-immigrant hate
Scapegoating is the tool of the opportunist — a tactic Donald Trump is utilizing in his presidential campaign to propagate hate against immigrants.30 minutes ago - Donald Trump -
The Hill - Politics
Haberman says Trump 'on edge' after second apparent assassination attempt
Senior political correspondent Maggie Haberman suggested Friday evening that former President Trump is feeling anxious following two assassination threats this election cycle. Her comments came in ...32 minutes ago - Donald Trump -
The Hill - Politics
The supreme crisis of Chief Justice John Roberts
Chief Justice John Roberts is facing a scandal after the New York Times published leaked confidential information from the Supreme Court, which could only have come from one of the nine members of ...55 minutes ago -
The Hill - Politics
Van Jones commends Harris for letting her 'guard down' with Oprah
CNN commentator Van Jones applauded Vice President Harris for letting her “guard down” during the Democratic presidential nominee's event with media mogul Oprah Winfrey. Jones praised the White ...1 hour ago